Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
In July, the RMB accounted for 3.1% of global payments via SWIFT, up from 3.10% in the previous month.
2026-08-20
In July, the RMB accounted for 3.1% of global payments via SWIFT, up from 3.10% in the previous month.
Back
Other News
2026-08-20
Goldman Sachs' trading desk points out that the internal structure of US stock momentum factors is undergoing significant changes. The report states that the overlap between 12-month winners and 3-month winners has fallen to multi-year lows, while th
Goldman Sachs' trading desk points out that the internal structure of US stock momentum factors is undergoing significant changes. The report states that the overlap between 12-month winners and 3-month winners has fallen to multi-year lows, while the overlap between 12-month winners and 3-month losers is nearing high levels, causing the 3-month momentum portfolio to begin deviating significantly from the 12-month momentum portfolio. This change is already reflected in sector weighting. Software currently has the largest weighting on the 3-month momentum bullish side and also the largest weighting on the 12-month momentum bearish side. On the same trading day, semiconductors fell by about 6.5%, while software rose by about 1%, indicating that market sentiment regarding "who the new winners are" within the technology sector is shifting.
2026-08-19
Market news: Novo Nordisk (NVO.N) has begun testing low-dose Wegovy oral tablets in a new obesity study.
Market news: Novo Nordisk (NVO.N) has begun testing low-dose Wegovy oral tablets in a new obesity study.
Chat with us
, powered by
LiveChat